Today we have a moderately speculative idea.: take shares in industrial enterprise Proto Labs (NYSE: PRLB), in order to capitalize on the growth of orders. Growth potential and validity: 12% behind 12 Months; 49% behind 3 of the year; 199% behind 10 years.
Teladoc Health (NYSE: TDOC) — the largest player in the telemedicine market. Telemedicine is a way of virtual patient care: consultations via messengers and video calls, virtual determination of the diagnosis and issuance of a prescription with sending it to the pharmacy. Previously, Tinkoff magazine has already published materials about this company.
Retail investors in Russia can be divided into "Slavophiles" and "Westerners". The first prefer domestic securities, the second attract foreign assets, mainly U.S. stocks. It will be useful for newcomers to the market to know, how fundamentally different are these two markets.
Soft drinks and snacks maker PepsiCo reports Q3 2021 results. Compared to the third quarter of last year: revenue increased by 11,6%, up to $20.2 billion; organic sales increased by 9%; operating profit increased by 4,9%, up to 3.2 billion; net profit fell by 2,9%, up to 2.2 billion.
Today we have an extremely speculative idea.: take promotions of cloud HR-service Cornerstone OnDemand (NASDAQ: BANKRUPTCY), in order to capitalize on the growth in demand as for the services of the company, as well as its shares. Growth potential and validity: 18% behind 14 Months; 11% per year for 15 years. Why stocks can go up: demand for company solutions will grow.
Today we have a speculative idea: take shares in military contractor Kratos Defense & Security Solutions (NASDAQ: KTOS), to capitalize on the growing interest in his field from investors. Growth potential and validity: 17% within 14 months; 48% in 4 years; 11% per year for 15 years.
Clothing and footwear manufacturer Levi Strauss has released its financial report for the third quarter of 2021.. Comparing with the previous year: revenue increased by 41%, up to 1.5 billion dollars; operating profit increased by 134%, up to 216 million; net profit increased from 27 up to 193 million.
Intercept Pharmaceuticals (NASDAQ: ICPT) - a biotechnology company from the USA, which in her research focuses on solving the problems of liver diseases. The business was founded in 2002 and listed its shares on the Nasdaq in 2012 - now they are trading close to the all-time low in the area 15 $. Where does the money come from? Like most biotechs, the company develops medicines and prepares them for commercialization in the US markets, Canada and Europe. Intercept Pharmaceuticals plans to produce synthetic analogs of bile acids, which will be used in the treatment of chronic liver diseases, such as primary biliary cholangitis, non-alcoholic steatohepatitis, cirrhosis of the liver and others. Portfolio of developed drugs The main developments of the company are based on obeticholic acid (OCA). The drug "Okaliva" based on it was approved by the Food and Drug Administration (FDA) in May 2016 and is prescribed by prescription for the treatment of primary biliary cholangitis. Intercept Pharmaceuticals plans to expand its sales market: filed for FDA approval for fibrosis, associated with non-alcoholic steatohepatitis; the third phase of clinical trials of the drug for use in the treatment of cirrhosis is underway, caused by non-alcoholic steatohepatitis; the second phase of clinical trials is underway for the combination of obeticholic acid and bezofibrate in the treatment of primary biliary cholangitis. The company has also begun preclinical development of a new generation of farnesoid receptor agonists. (FXR). Что плохого Объем коротких позиций в акциях компании, по данным Finviz, exceeds 30%, which puts strong pressure on prices, which have reached historic lows this year. Commitments have been growing since 2019 and as of August 2021 are 139% from business assets. The greater the debt, тем больше денег будет уходить на его обслуживание — в случае повышения процентной ставки …
Обзор Intercept Pharmaceuticals: so that the liver does not hurt Read more
Today we have a moderately speculative idea.: take stock of the manufacturer of computer devices Corsair Gaming (NASDAQ: CRSR), in order to capitalize on the growing popularity of its products. Growth potential and validity: 18% for 12 months; 77% in 4 years; 150% for 10 years.
Today we have a very speculative idea: take stock of digital advertising software manufacturer DoubleVerify Holdings (NYSE: DV), in order to make money on the positive market conditions. Growth potential and validity: 16,5% behind 14 Months; 37% behind 4 of the year.